Results
EORTC Melanoma Group Autumn Meeting
17 May 2023
Event
The EORTC Melanoma Group Autumn meeting will be held in Manchester, UK on 5-6 October 2023. It is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC [...]
EORTC Melanoma Group Spring Meeting
4 Jan 2023
Event
The EORTC Melanoma Group Spring Meeting will be held as a face-to-face event in Berlin, Germany on 23-24 March and is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member [...]
New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022
9 Sep 2022
Post
Important new results from EORTC trials will be presented at this year's ESMO conference starting tomorrow (October 9) in Paris. Once again, immunotherapy - the use of drugs that stimulate the immune system so that it can find and attack cancer cells – plays a leading role, as do studies into patients’ quality of [...]
EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma
5 Aug 2022
Post
Brussels, August 05, 2022 – The European Organisation for Research and Treatment of Cancer (EORTC) has finished patient recruitment for the EORTC-1612-MG trial in patients with unresected or metastatic melanoma. The randomised trial will study the effect of combined targeted therapy (encorafenib and binimetinib) followed by combined immunotherapy (ipilimumab and nivolumab) as compared to [...]
EORTC Melanoma Group Autumn Meeting
10 Jun 2022
Event
The EORTC Melanoma Group Autumn Meeting will be held in Perugia, Italy on 27-28 October 2022 (face-to-face event). It is only open to individual or site staff members of the group. The link to register was sent by email. Click here to download the preliminary agenda. Click here to view the Melanoma pathobiology course. Venue GRAND HOTEL ASSISI **** Via [...]
Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
24 May 2022
Post
Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) today announced the screening of the first patient with a resected stage II BRAF-mutant melanoma for the phase III study COLUMBUS-AD (NCT05270044; EORTC-2139-MG). COLUMBUS-AD is a pioneering study to evaluate whether the combination of BRAF and MEK inhibitors encorafenib (Braftovi®) and binimetinib [...]
